MX2023006811A - Compuestos novedosos. - Google Patents
Compuestos novedosos.Info
- Publication number
- MX2023006811A MX2023006811A MX2023006811A MX2023006811A MX2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A MX 2023006811 A MX2023006811 A MX 2023006811A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- novel compounds
- properties
- glp
- glucagon
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000813 peptide hormone Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona compuestos novedosos que son análogos de hormonas peptídicas y que son útiles en el tratamiento de trastornos tales como la diabetes y la obesidad. Los compuestos de la secuencia general descrita en la especificación poseen un perfil adaptado con respecto a las propiedades de potencia en los receptores de glucagón y GLP-1. Con respecto a las propiedades in vivo, se ha demostrado que la administración de péptidos de ejemplo de la invención, en modelos animales, produce un aumento de la pérdida de peso. Los compuestos preferidos lo consiguen sin reducir significativamente el consumo de alimentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2019588.9A GB202019588D0 (en) | 2020-12-11 | 2020-12-11 | Novel Compounds |
| GBGB2110809.7A GB202110809D0 (en) | 2021-07-27 | 2021-07-27 | Novel compounds |
| PCT/GB2021/053249 WO2022123271A1 (en) | 2020-12-11 | 2021-12-10 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006811A true MX2023006811A (es) | 2023-07-12 |
Family
ID=79021073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006811A MX2023006811A (es) | 2020-12-11 | 2021-12-10 | Compuestos novedosos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336669A1 (es) |
| EP (1) | EP4259646A1 (es) |
| JP (1) | JP2024501467A (es) |
| KR (1) | KR20230125802A (es) |
| AU (1) | AU2021397877A1 (es) |
| CA (1) | CA3199733A1 (es) |
| GB (1) | GB2616205A (es) |
| IL (1) | IL303549A (es) |
| MX (1) | MX2023006811A (es) |
| WO (1) | WO2022123271A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
| US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| JP5518282B2 (ja) * | 2003-09-01 | 2014-06-11 | ノヴォ ノルディスク アー／エス | 安定なペプチドの製剤 |
| MX2007011307A (es) * | 2005-03-18 | 2007-10-08 | Novo Nordisk As | Compuestos de glp-1 extendidos. |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| EP2650006A1 (en) * | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
| EP2413955A4 (en) * | 2009-04-01 | 2012-12-26 | Amylin Pharmaceuticals Inc | AGONIST COMPOUNDS OF GLP-1 RECEPTORS HAVING CONFORMATIONAL CONSTRAINTS AT THEIR N-TERMINAL END |
| CN103003300B (zh) * | 2010-04-27 | 2017-06-09 | 西兰制药公司 | Glp‑1受体激动剂和胃泌素的肽缀合物及其用途 |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| GB201404002D0 (en) | 2014-03-06 | 2014-04-23 | Imp Innovations Ltd | Novel compounds |
| CN104211801A (zh) * | 2014-07-25 | 2014-12-17 | 杭州诺泰制药技术有限公司 | 一种制备利西拉来的方法 |
| WO2017178829A1 (en) | 2016-04-15 | 2017-10-19 | Imperial Innovations Limited | Peptide analogues |
-
2021
- 2021-12-10 WO PCT/GB2021/053249 patent/WO2022123271A1/en active Application Filing
- 2021-12-10 EP EP21830477.2A patent/EP4259646A1/en active Pending
- 2021-12-10 CA CA3199733A patent/CA3199733A1/en active Pending
- 2021-12-10 IL IL303549A patent/IL303549A/en unknown
- 2021-12-10 AU AU2021397877A patent/AU2021397877A1/en active Pending
- 2021-12-10 JP JP2023535761A patent/JP2024501467A/ja active Pending
- 2021-12-10 GB GB2309024.4A patent/GB2616205A/en active Pending
- 2021-12-10 KR KR1020237023291A patent/KR20230125802A/ko unknown
- 2021-12-10 US US18/266,571 patent/US20240336669A1/en active Pending
- 2021-12-10 MX MX2023006811A patent/MX2023006811A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021397877A9 (en) | 2024-06-20 |
| AU2021397877A1 (en) | 2023-07-06 |
| EP4259646A1 (en) | 2023-10-18 |
| US20240336669A1 (en) | 2024-10-10 |
| WO2022123271A1 (en) | 2022-06-16 |
| CA3199733A1 (en) | 2022-06-16 |
| KR20230125802A (ko) | 2023-08-29 |
| IL303549A (en) | 2023-08-01 |
| JP2024501467A (ja) | 2024-01-12 |
| GB2616205A (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550154A1 (en) | Gip/glp1 co-agonist compounds. | |
| PH12020551742A1 (en) | Gip derivatives and uses thereof | |
| MX2023010869A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
| EP2422808A2 (en) | Novel compounds and their effects on feeding behaviour | |
| MX2020007410A (es) | Formulaciones, composiciones y métodos farmacéuticos de péptido yy. | |
| EA201991345A1 (ru) | Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip | |
| AR061203A1 (es) | Moduladores del receptor glp-1 modificados en la terminal n | |
| PE20160683A1 (es) | Analogos de glucagon acilados | |
| ZA200606153B (en) | Intranasal administration of glucose-regulating peptides | |
| NZ746784A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| JP2008543816A (ja) | 新規化合物および該化合物が摂食行動に及ぼす効果 | |
| PH12021550964A1 (en) | Protein tyrosine-tyrosine analogs and methods of using the same. | |
| MX2023006811A (es) | Compuestos novedosos. | |
| MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
| MX2024007688A (es) | Analogos novedosos de glp-1. | |
| SA522432563B1 (ar) | نظير ببتيد أوكسينتو موديولين معالج بأسيل | |
| MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
| ZA202301635B (en) | Ham15-52 analogues with improved amylin receptor (hamy3r) potency | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| RU2020131381A (ru) | Композиция glp-1 для лечения ожирения и регулирования веса | |
| MX2021012177A (es) | Usos terapeuticos de dulaglutida. | |
| EA202191511A1 (ru) | Составы на основе аналога пептида оксинтомодулина | |
| EA202092017A1 (ru) | Новые аналоги glp-1 | |
| EA202192094A1 (ru) | Аналог агониста глюкагоноподобного пептида-1 (glp-1), способ его получения и применение |